BridgeMD
New treatment option for Breast Cancer
Official title CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
ClinicalTrials.gov ID: NCT05206331
What this study is testing
What is Iodinated Contrast Media (ICM)?
Iodinated Contrast Media (ICM) is an investigational medicine, being studied as a potential treatment for breast cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- One of the primary criticisms of mammography is that it leads to unneeded stress and anxiety from identification and biopsy of non-cancerous findings. Contrast-enhanced mammography (CEM) has the potential to significantly reduce biopsy rates for commonly seen benign breast lesions while preserving very high cancer detection.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 and older, women only. Healthy volunteers may be eligible.
You may be able to join if
- Subject is female of any race and ethnicity
- Subject is ≥30 years old
- Subject is diagnosed with a suspicious breast abnormality and is scheduled for an imaging directed breast biopsy.
You likely can't join if
- Subject is unable or unwilling to undergo informed consent
- Subject has a breast implant in the breast of interest
- Subject is pregnant
- Subject is breast-feeding
- Subject is actively being treated for cancer of any type with chemotherapy
- Subject has reduced kidney function with eGFR \< 30.
See the full eligibility criteria
- Subject is female of any race and ethnicity
- Subject is ≥30 years old
- Subject is diagnosed with a suspicious breast abnormality and is scheduled for an imaging directed breast biopsy.
- Subject is unable or unwilling to undergo informed consent
- Subject has a breast implant in the breast of interest
- Subject is pregnant
- Subject is breast-feeding
- Subject is actively being treated for cancer of any type with chemotherapy
- Subject has reduced kidney function with eGFR \< 30.
- Subject has had a prior reaction to iodinated contrast; thus a known allergy to iodinated contrast
The study team makes the final eligibility decision.
Where it's taking place
- Pittsburgh, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 30 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Pittsburgh, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.